Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CTI

Novartis day

Trial sets up showdown between Ibrance and Novartis’ ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval

- PMLiVE

Pfizer adds eczema drug with $5.2bn Anacor acquisition

Expands innovative products business with non-steroidal therapy Crisaborole

- PMLiVE

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

Will collaborate on five programmes to explore the cause of genetically defined diseases

regeneron headquarters

Regeneron says anti-NGF fasinumab works in pain

Clinical trial shows promise for opioid alternative

- PMLiVE

Pfizer split still on cards – for tax reasons

Firm continues to look for ways to reduce tax burden

- PMLiVE

Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects

EAGLES trial of 8,000 patients backs the smoking cessation drugs' safety

- PMLiVE

Pfizer joins up with IBM for internet-of-things collaboration

Aims to develop an IoT remote monitoring system for Parkinson’s patients

- PMLiVE

Sanofi opens UK bioscience partnering office

Locates new unit at the Stevenage Bioscience Catalyst

- PMLiVE

US tax changes claim Pfizer scalp as Allergan deal abandoned

Firm walks away from record-breaking $160bn merger after planned inversion rule changes released

- PMLiVE

FDA approves first Remicade biosimilar

Pfizer-Celltrion's Inflectra becomes the second biosimilar to be licensed in the US

- PMLiVE

Pfizer’s PCSK9 inhibitor clears another phase III trial

Bococizumab will compete with Praluent and Repatha if it reaches the market

- PMLiVE

Positive trials bring Pfizer closer to new use for Xeljanz

Rheumatoid arthritis drug performs in two ulcerative colitis trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links